Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma

Jonathan Geoffrey Ayres, B. Higgins, E. R. Chilvers, G. Ayre, M. Blogg, Helen Catherine Fox

    Research output: Contribution to journalArticle

    221 Citations (Scopus)

    Abstract

    Background: Patients with poorly controlled asthma have greater morbidity and mortality. This study evaluated the efficacy and tolerability of omalizumab in patients with poorly controlled, moderate-to-severe allergic asthma.

    Methods: This was a randomized, open-label, multicentre, parallel-group study. A total of 312 patients (12-73 years) receiving greater than or equal to400 mug/day (adolescent) or greater than or equal to800 mug/day (adult) inhaled beclomethasone dipropionate, or equivalent were included. Patients received best standard care (BSC) with or without omalizumab [at least 0.016 mg/kg/IgE (IU/ml) every 4 weeks] for 12 months.

    results: The annualized mean number of asthma deterioration-related incidents was reduced from 9.76 with BSC alone (n = 106) to 4.92 per patient-year with omalizumab (n = 206) (P < 0.001). Mean clinically significant asthma exacerbation rates were 2.86 and 1.12 per patient-year, respectively (P < 0.001). Omalizumab-treated patients (41.4%) required rescue medication <1 day/week compared with 20.7% for BSC alone (P < 0.001). Omalizumab improved absolute forced expiratory volume in 1 s (FEV1) compared with BSC alone (2.48 and 2.28l, respectively; P < 0.05) and reduced symptom scores relative to BSC alone (decrease of 6.5 and 0.7 respectively; P < 0.001). Omalizumab was well-tolerated.

    Conclusions: Omalizumab administered as add-on therapy to BSC benefits patients with poorly controlled, moderate-to-severe allergic asthma.

    Original languageEnglish
    Pages (from-to)701-708
    Number of pages7
    JournalAllergy
    Volume59
    Issue number7
    DOIs
    Publication statusPublished - 2004

    Keywords

    • asthma deterioration-related incidents
    • allergic asthma
    • anti-immunoglobulin E
    • exacerbations
    • omalizumab
    • ANTIBODY

    Cite this

    Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. / Ayres, Jonathan Geoffrey; Higgins, B.; Chilvers, E. R.; Ayre, G.; Blogg, M.; Fox, Helen Catherine.

    In: Allergy, Vol. 59, No. 7, 2004, p. 701-708.

    Research output: Contribution to journalArticle

    Ayres, Jonathan Geoffrey ; Higgins, B. ; Chilvers, E. R. ; Ayre, G. ; Blogg, M. ; Fox, Helen Catherine. / Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. In: Allergy. 2004 ; Vol. 59, No. 7. pp. 701-708.
    @article{f7a0911f3c404a6193b368beb44636eb,
    title = "Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma",
    abstract = "Background: Patients with poorly controlled asthma have greater morbidity and mortality. This study evaluated the efficacy and tolerability of omalizumab in patients with poorly controlled, moderate-to-severe allergic asthma.Methods: This was a randomized, open-label, multicentre, parallel-group study. A total of 312 patients (12-73 years) receiving greater than or equal to400 mug/day (adolescent) or greater than or equal to800 mug/day (adult) inhaled beclomethasone dipropionate, or equivalent were included. Patients received best standard care (BSC) with or without omalizumab [at least 0.016 mg/kg/IgE (IU/ml) every 4 weeks] for 12 months.results: The annualized mean number of asthma deterioration-related incidents was reduced from 9.76 with BSC alone (n = 106) to 4.92 per patient-year with omalizumab (n = 206) (P < 0.001). Mean clinically significant asthma exacerbation rates were 2.86 and 1.12 per patient-year, respectively (P < 0.001). Omalizumab-treated patients (41.4{\%}) required rescue medication <1 day/week compared with 20.7{\%} for BSC alone (P < 0.001). Omalizumab improved absolute forced expiratory volume in 1 s (FEV1) compared with BSC alone (2.48 and 2.28l, respectively; P < 0.05) and reduced symptom scores relative to BSC alone (decrease of 6.5 and 0.7 respectively; P < 0.001). Omalizumab was well-tolerated.Conclusions: Omalizumab administered as add-on therapy to BSC benefits patients with poorly controlled, moderate-to-severe allergic asthma.",
    keywords = "asthma deterioration-related incidents, allergic asthma, anti-immunoglobulin E, exacerbations, omalizumab, ANTIBODY",
    author = "Ayres, {Jonathan Geoffrey} and B. Higgins and Chilvers, {E. R.} and G. Ayre and M. Blogg and Fox, {Helen Catherine}",
    year = "2004",
    doi = "10.1111/j.1398-9995.2004.00533.x",
    language = "English",
    volume = "59",
    pages = "701--708",
    journal = "Allergy",
    issn = "0105-4538",
    publisher = "John Wiley & Sons, Ltd (10.1111)",
    number = "7",

    }

    TY - JOUR

    T1 - Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma

    AU - Ayres, Jonathan Geoffrey

    AU - Higgins, B.

    AU - Chilvers, E. R.

    AU - Ayre, G.

    AU - Blogg, M.

    AU - Fox, Helen Catherine

    PY - 2004

    Y1 - 2004

    N2 - Background: Patients with poorly controlled asthma have greater morbidity and mortality. This study evaluated the efficacy and tolerability of omalizumab in patients with poorly controlled, moderate-to-severe allergic asthma.Methods: This was a randomized, open-label, multicentre, parallel-group study. A total of 312 patients (12-73 years) receiving greater than or equal to400 mug/day (adolescent) or greater than or equal to800 mug/day (adult) inhaled beclomethasone dipropionate, or equivalent were included. Patients received best standard care (BSC) with or without omalizumab [at least 0.016 mg/kg/IgE (IU/ml) every 4 weeks] for 12 months.results: The annualized mean number of asthma deterioration-related incidents was reduced from 9.76 with BSC alone (n = 106) to 4.92 per patient-year with omalizumab (n = 206) (P < 0.001). Mean clinically significant asthma exacerbation rates were 2.86 and 1.12 per patient-year, respectively (P < 0.001). Omalizumab-treated patients (41.4%) required rescue medication <1 day/week compared with 20.7% for BSC alone (P < 0.001). Omalizumab improved absolute forced expiratory volume in 1 s (FEV1) compared with BSC alone (2.48 and 2.28l, respectively; P < 0.05) and reduced symptom scores relative to BSC alone (decrease of 6.5 and 0.7 respectively; P < 0.001). Omalizumab was well-tolerated.Conclusions: Omalizumab administered as add-on therapy to BSC benefits patients with poorly controlled, moderate-to-severe allergic asthma.

    AB - Background: Patients with poorly controlled asthma have greater morbidity and mortality. This study evaluated the efficacy and tolerability of omalizumab in patients with poorly controlled, moderate-to-severe allergic asthma.Methods: This was a randomized, open-label, multicentre, parallel-group study. A total of 312 patients (12-73 years) receiving greater than or equal to400 mug/day (adolescent) or greater than or equal to800 mug/day (adult) inhaled beclomethasone dipropionate, or equivalent were included. Patients received best standard care (BSC) with or without omalizumab [at least 0.016 mg/kg/IgE (IU/ml) every 4 weeks] for 12 months.results: The annualized mean number of asthma deterioration-related incidents was reduced from 9.76 with BSC alone (n = 106) to 4.92 per patient-year with omalizumab (n = 206) (P < 0.001). Mean clinically significant asthma exacerbation rates were 2.86 and 1.12 per patient-year, respectively (P < 0.001). Omalizumab-treated patients (41.4%) required rescue medication <1 day/week compared with 20.7% for BSC alone (P < 0.001). Omalizumab improved absolute forced expiratory volume in 1 s (FEV1) compared with BSC alone (2.48 and 2.28l, respectively; P < 0.05) and reduced symptom scores relative to BSC alone (decrease of 6.5 and 0.7 respectively; P < 0.001). Omalizumab was well-tolerated.Conclusions: Omalizumab administered as add-on therapy to BSC benefits patients with poorly controlled, moderate-to-severe allergic asthma.

    KW - asthma deterioration-related incidents

    KW - allergic asthma

    KW - anti-immunoglobulin E

    KW - exacerbations

    KW - omalizumab

    KW - ANTIBODY

    U2 - 10.1111/j.1398-9995.2004.00533.x

    DO - 10.1111/j.1398-9995.2004.00533.x

    M3 - Article

    VL - 59

    SP - 701

    EP - 708

    JO - Allergy

    JF - Allergy

    SN - 0105-4538

    IS - 7

    ER -